Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Roche Holdings Ltd ADR (RHHBY)

Roche Holdings Ltd ADR (RHHBY)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Roche Holdings Ltd ADR GRENZACHERSTRASSE 124 BASEL V8 CH-4070 CHE

www.roche.com P: 41-61-688-1111

Description:

Basel, Switzerland-based Roche Holding Ltd. is a leading health care company focused on developing and commercializing innovative diagnostic and therapeutic products and services, which enable early detection and prevention of diseases as well as their treatment and monitoring. The company conducts its operations through two segments ' Pharmaceuticals and Diagnostics.Pharmaceuticals: Key focus areas in this segment include Oncology, Virology, Inflammation, Metabolism and Neuroscience. Diagnostics: The Diagnostics Division operates in four segments ' Roche Professional Diagnostics, Roche Diabetes Care, Roche Molecular Diagnostics, and Roche Tissue Diagnostics. In September 2014, Roche acquired InterMune for $8.3 billion and added Esbriet to its portfolio. During the first quarter of 2018, Roche acquired Flatiron Health and Ignyta, Inc.

Key Statistics

Overview:

Market Capitalization, $K 203,192,496
Enterprise Value, $K 229,740,064
Shares Outstanding, K 6,830,000
Annual Sales, $ 67,325 M
Annual Net Income, $ 12,808 M
EBIT, $ 0 K
EBITDA, $ 21,007 M
60-Month Beta 0.41
% of Institutional Shareholders 0.00%
Float, K 0
% Float 0.00%
Short Volume Ratio 0.06

Growth:

1-Year Return -25.83%
3-Year Return -30.55%
5-Year Return -8.73%
5-Year Revenue Growth 10.68%
5-Year Earnings Growth 11.21%
5-Year Dividend Growth -10.11%

Per-Share Information:

Latest Earnings Date 02/01/24
Earnings Per Share ttm 0.00
Annual Dividend Rate, $ 0.85
Annual Dividend Yield 2.85%
Most Recent Dividend 0.847 on 03/14/24
Next Ex-Dividends Date 03/14/24
Dividend Payable Date 05/03/24
Dividend Payout Ratio 0.00%
Most Recent Split 2-1 on 02/27/14

RHHBY Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward 12.28
Price/Earnings to Growth 5.01
Return-on-Equity % 0.00%
Return-on-Assets % 0.00%
Profit Margin % 19.02%
Debt/Equity 0.88
Price/Sales N/A
Price/Cash Flow 9.76
Price/Book 6.14
Book Value/Share 0.00
Interest Coverage 15.14

RHHBY Dividends

Date Value
03/14/24 $0.8470
03/16/23 $0.8020
03/17/22 $0.7760
03/18/21 $0.7730
03/19/20 $0.7190
03/07/19 $0.6780
03/15/18 $0.9180
03/15/17 $0.8380
03/02/16 $0.8490
03/04/15 $0.8940
03/06/14 $0.6940
02/28/05 $0.6970
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar